Related Experiment Videos
Ifosfamide, Fanconi's syndrome, and rickets
C B Pratt1, W H Meyer, J J Jenkins
1Department of Hematology-Oncology, St Jude Children's Research Hospital, Memphis, TN 38101-0318.
Summary
Children receiving ifosfamide chemotherapy, especially those previously treated with cisplatin or carboplatin, face a higher risk of developing Fanconi's renal syndrome. This rare but serious side effect requires careful consideration of prior therapies and ifosfamide dosage.
Area of Science:
- Pediatric Oncology
- Nephrology
- Pharmacology
Background:
- Ifosfamide is a chemotherapy agent used in pediatric oncology.
- Mesna is a uroprotectant co-administered with ifosfamide to mitigate bladder toxicity.
- Fanconi's renal syndrome is a rare but serious adverse effect associated with ifosfamide treatment.
Observation:
- Three out of 218 children developed Fanconi's renal syndrome.
- All affected children were part of a subgroup of 86 who had also received cisplatin or carboplatin.
- A statistically significant higher risk (P = .04) was observed in patients with prior cisplatin/carboplatin exposure.
Findings:
- Prior exposure to nephrotoxic agents like cisplatin or carboplatin significantly increases the risk of ifosfamide-induced Fanconi's renal syndrome.
- The total cumulative dose of ifosfamide may also play a role in the development of this syndrome.
- This adverse event appears to be irreversible.
Implications:
- Clinicians should carefully assess prior nephrotoxic therapy when considering ifosfamide treatment in children.
- Dosage adjustments and vigilant monitoring for renal dysfunction are crucial in high-risk pediatric patients.
- Further research into the mechanisms and prevention of ifosfamide-induced nephrotoxicity is warranted.